Putting It All Together: How Do Primary Care Physicians Interpret and Use the Results of Prevention Trials?

The document discussed the low uptake of cancer chemoprevention drugs, such as tamoxifen for breast cancer and finasteride for prostate cancer, by primary care physicians despite evidence of their effectiveness in reducing cancer incidence. Several barriers were identified, including concerns about side effects, uncertainty about the duration of benefits, discomfort with using drugs also used for treatment, lack of patient demand, high costs, and the time required for risk assessment and decision-making. The US Preventive Services Task Force had recommended breast cancer chemoprevention but not prostate cancer. The authors emphasized the need for more research to understand these barriers and suggested that increasing the use of chemopreventive agents would require developing safer, more affordable options and effective promotion to both physicians and at-risk individuals.